Library of Slides and Posters

Hepatitis C - Library of Slides and Posters

PegIntron + Ribavirin

•	Response to Peginterferon alfa-2b and Ribavirin for Chronic Hepatitis C in Patients With Body Weight Ён125 kg: Results From the WIN-R Trial I Jacobson and others. Poster #369.
•	An Interim Analysis of the Canadian POWeR Program (Pegetron Prospective Optimal Weight-Based Dosing Response): Consistent SVR Rates Across All Weight Categories P Marotta and others. Poster #358.
•	Pegylated Interferon alfa-2b + Ribavirin Is Equally Efficacious and Well Tolerated in Patients >65 Years Old in Comparison to Other Age Groups: Subanalysis of a Randomized, Controlled Study (WIN-R Trial) S Flamm and others. Poster #338.
•	Prospective Analysis of Sustained Virologic Response to PEG-Interferon alfa-2b and Ribavirin Treatment in Asian and Hispanic Patients With Chronic Hepatitis C: Results From the WIN-R Trial B Freilich and others. Poster #349.
•	Pegylated Interferon alfa-2b Plus Ribavirin in Patients With Genotype 1 Chronic Hepatitis C With a Slow Virologic Response: A Preliminary Report of the SUCCESS Study M Buti and others. Poster #404.
•	Risk Factors for Relapse in Genotype 3 High Viral Load Patients With Hepatitis C in the WIN-R Trial R Brown and others. Poster #1132.
•	HCV RNA Negativity After 12 Weeks of Therapy Is the Best Predictor of Sustained Viral Response (SVR) in the Re-treatment of Previous Interferon alfa/Ribavirin Nonresponders (NR): Results From the EPIC3 Program T Poynard and others. Poster #1123.